Abstract
Pharmaceutical policy development is a linear and step-wise process that moves from problem statement or agenda setting, to planning and analysis, to definitions and objectives, to policy formulation and statutory approval, to implementation and monitoring, to policy review and evaluation and finally to improvisation. In the process of developing and implementing such a policy framework several stakeholders including national and multi-national drug manufacturers, state and central governments (including all ministries like health, commerce, trade, industry), regulatory authorities, patients, doctors, pharmacists, pharmaceutical traders, insurance agencies, academia, professional associations, NGOs, civil society and consumer groups assume primary importance without whose active involvement the whole process would be inadequate and sometimes even inappropriate leaving huge gaps in their comprehensiveness, inclusiveness and acceptability. This chapter defines the role and describes the importance of these very stakeholders in the process of pharmaceutical policy development and implementation in any settings across the world.
Reference37 articles.
1. WHO. How to Develop and Implement a National Drug Policy. Second ed. Geneva: World Health Organization, WHO; 2001. p. 4
2. Chan J. A Tool for the Public Policy Process & Stakeholder Engagement: Using co-design methodologies and principles, how might we support policy makers and policy influencers to adopt a user-centered approach to the public policy process and build rapport between stakeholders? [Masters dissertation] submitted to OCAD University in partial fulfillment of the requirements for the degree of Masters of Design in Strategic Foresight and Innovation. Toronto, Ontario, Canada. 2016
3. Chadha A. Reguatory Issues in the Indian Pharmaceutical Industry. 2008. Available from: http://shodhganga.inflibnet.ac.in/bitstream/10603/114212/6/chapter-5.pdf. [Accessed: April 26, 2022]
4. WHO. World Medicines Situation Report 2011. 3rd ed. Available from: http://apps.who.int/medicinedocs/documents/s20054en/s20054en.pdf. [Accessed: April 26, 2022]
5. Light DW, Lexchin J. Foreign free riders and the high price of US medicines. BMJ. 2005;331:958-960
Cited by
2 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献